secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viridian Therapeutics, Inc.\DE (VRDN)
CIK:        0001590750
Form:       8-K
Filed at:   2025-05-20T23:59:59+00:00
Accession:  0001193125-25-122821
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viridian: 70% of veligrotug proptosis responders maintain response at week 52 in THRIVE trial
--------------------------------------------------------------------------------

- 70% of veligrotug proptosis responders (21/30) in THRIVE maintained response at week 52, defined as ≥2 mm reduction from baseline without fellow eye worsening.
- Safety profile unchanged in follow-up; majority of adverse events resolved by week 52.
- BLA submission for veligrotug in TED on track for H2 2025; company preparing for potential U.S. launch in 2026.
- Veligrotug received Breakthrough Therapy Designation, supporting Priority Review eligibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525122821/0001193125-25-122821-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1590750/000119312525122821/d938560d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-122821

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer